Meeder Asset Management’s TG Therapeutics TGTX Stock Holding History

Meeder Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50	Closed	-$1.8K	–	942
2025 Q2	$1.8K	Sell	50 -23,967	-100%	-$892K	﹤0.01%	819
2025 Q1	$947K	Buy	24,017 +23,943	+32,355%	+$806K	0.06%	137
2024 Q4	$2.23K	Buy	+74	New	+$2.12K	﹤0.01%	885
2023 Q2	–	Sell	-803	Closed	-$12.1K	–	602
2023 Q1	$12.1K	Buy	+803	New	+$12.2K	﹤0.01%	493
2021 Q2	–	Sell	-2,575	Closed	-$123K	–	2655
2021 Q1	$123K	Buy	+2,575	New	+$124K	0.01%	861
2020 Q4	–	Sell	-5,571	Closed	-$148K	–	2211
2020 Q3	$148K	Buy	5,571 +251	+5%	+$5.78K	0.01%	681
2020 Q2	$105K	Buy	5,320 +3,195	+150%	+$51.5K	0.01%	753
2020 Q1	$21K	Buy	+2,125	New	+$26.8K	﹤0.01%	1231
2019 Q3	–	Sell	-622	Closed	-$5K	–	2261
2019 Q2	$5K	Buy	+622	New	+$4.7K	﹤0.01%	1680
2017 Q3	–	Sell	-315	Closed	-$3K	–	1759
2017 Q2	$3K	Hold	315	–	–	﹤0.01%	1338
2017 Q1	$4K	Sell	315 -3,071	-91%	-$22K	﹤0.01%	1181
2016 Q4	$16K	Buy	+3,386	New	+$19.9K	﹤0.01%	685

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Meeder Asset Management's TGTX Position: Q3 2025 in Review

Meeder Asset Management sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 50 shares — an estimated $1.8K sold.

Meeder Asset Management first reported a position in TGTX in Q4 2016 and held it in 12 quarters. The position peaked at $947K in Q1 2025. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

Meeder Asset Management reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
Meeder Asset Management sold 50 TG Therapeutics shares in Q3 2025, an estimated $1.8K.
Meeder Asset Management first reported a position in TG Therapeutics in Q4 2016 and held it in 12 quarters.
Meeder Asset Management's TG Therapeutics position peaked at $947K in Q1 2025.
354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Meeder Asset Management's 13F filing for Q3 2025, filed 24 Oct 2025.